Acrivon Therapeutics, Inc. (ACRV) has issued an announcement.
Acrivon Therapeutics, Inc. has appointed Santhosh Palani, Ph.D., CFA, as a new director starting March 4, 2024. Dr. Palani’s selection as a director is based solely on merit without any external arrangements. He will be compensated with a stock option grant of 32,500 shares and cash, following the company’s standard practices for non-employee directors. No reportable transactions involving Dr. Palani exist under SEC regulations.
See more data about ACRV stock on TipRanks’ Stock Analysis page.
